

The use of total funds channeled through “la Caixa” to Gavi programmes in 2018

Final Report to the "la Caixa"
Foundation (for Gavi)

May 2019



Executive Summary

The “la Caixa” Foundation and GAVI partnership is aimed at protecting the lives of the world’s most disadvantaged children, with a specific focus on providing life-saving protection against pneumonia by funding pneumococcal vaccine. In 2018 this partnership has contributed funds to vaccinate an estimated 890,306 children in Mozambique. This would correspond to a 65% increase compared to the 2017 figures.

In 2018, the “la Caixa” Foundation alone contributed \$ 4,560,318 to Gavi which helped vaccinate an estimated 445,153 children in Mozambique.

Thanks to the generosity of the “la Caixa” Foundation, “la Caixa” employees, the Business Alliance for Child Vaccinations, and microdonations from the Spanish public, The Bill and Melinda Gates Foundation have matched your funds to thus double the impact.

“la Caixa” Foundation has channeled \$ 9,120,636 to Gavi in 2018. This corresponds to a 55% increase compared to the 2017 figures.

Table of Contents

1. Overview of use of « la Caixa » funds in 2018
2. Background information on pneumonia and Mozambique
3. Gavi Matching Fund Report

1

Overview of the use of 2018 funds

2018 Contribution and Impact

“la Caixa” 2018 Contributions:

- “la Caixa” Foundation: \$ 2,278,220 (€ 2,017,783)
- Business Alliance: \$ 2,117,411 (€ 1,868,854)
- Employees and Microdonations: \$ 164,715 (€ 148,929)

Total: \$ 4,560,318 (€ 4,035,566)**

The Gavi Matching Fund doubled your contributions with ≈ \$ 4,560,318** from the Bill and Melinda Gates Foundation



Projected Impact:

- **3,053,638 doses*** of pneumococcal vaccine were purchased
- **Approximately 890,306 children immunized*****

*Note: All impact calculations are estimates.
*total includes possible indicative number of doses purchased with funds from the Gavi Matching Fund
**All Gavi Matching Fund contributions are recorded in US dollars
*** This number acknowledges a 10% wastage*

Detailed breakdown of La Caixa's funds for pneumococcal vaccines and impact

Use of funds and impact in Mozambique				Total La Caixa
	La Caixa Foundation	Employees & Microdonations	Business Alliance	Investment amount
Funds (USD)	\$ 2,278,220 €2,017,783 **	\$ 164,715 €148,929 **	\$ 2,117,411 €1,868,854 **	\$ 4,560,318 €4,035,566 **
Doses purchased*	762,760*	55,147*	708,921*	1,526,828*
Children immunized	222,386	16,078	206,689	445,153
Funds (%)	50%	4%	46%	100%

*These numbers include the 10% wastage. Total includes possible indicative number of doses purchased with La Caixa Funds (only)

** These figures are reported by la Caixa and not validated by Gavi.

Note: All impact calculations are estimates. Adjustments from the preliminary report, as well as an increase in funds disbursed vs. funds received, reflect currency adjustments, interest earned, and fluctuations in the global weighted average cost of vaccines.

The prices shared for each vaccine is the Weighted Average Price. We use the WAP as we have multiple presentations of each vaccine and a mix of the presentations is bought by Gavi programs each year. In this case, the \$ 2.99 represents a WAP for PCV based off the 2018 UNICEF price list and weighted in proportion to volumes of each presentation procured the previous year.

The 2018 UNICEF price list is here: https://www.unicef.org/supply/files/Product_Menu_Feb_2019.pdf

Detailed breakdown of funds matched by Bill and Melinda Gates Foundation (Matching Fund)

Year	Funding Source	Country	Vaccine	Funds Matched (%)	Funds Matched (USD)	Doses Purchased	Children Immunized
2018	Total La Caixa Investment	Mozambique	Pneumococcal	100%	\$ 9,120,636	3,101,116*	890,306
2018	La Caixa Foundation	Mozambique	Pneumococcal	100%	\$ 2,278,220	762,760*	222,386
2018	Employees and Microdonations	Mozambique	Pneumococcal	100%	\$164,715	55,147*	16,078
2018	Business Alliance	Mozambique	Pneumococcal	100%	\$ 2,117,411	708,921*	206,689

*These numbers include the 10% wastage.

Note: These numbers include the 10% wastage. Total includes possible indicative number of doses with La Caixa Funds (only). These figures are reported by la Caixa and not validated by Gavi.

The prices shared for each vaccine is the Weighted Average Price. We use the WAP as we have multiple presentations of each vaccine and a mix of the presentations is bought by Gavi programs each year. In this case, the \$ 2.99 represents a WAP for PCV based off the 2018 UNICEF price list and weighted in proportion to volumes of each presentation procured the previous year.

The 2018 UNICEF price list is here: https://www.unicef.org/supply/files/Product_Menu_Feb_2019.pdf

The total contributions for 2018 are €2,017,783

Business Alliance: \$ 2,117,411
(€ 1,868,854)**

569 companies - €922,090

3,426 Private Banking donations – €946,746

Employees & Microdonations: \$ 164,715
(€ 148,929)**

760 employees - €44,731

61,799 microdonations - €104,198


*** These figures are reported by la Caixa and not validated by Gavi*

2

Background information on pneumonia and recipient country

The challenge: pneumonia and pneumococcal vaccine

CAUSES OF DEATHS AMONG CHILDREN UNDER 5 YEARS, 2017



Source: Estimates generated by WHO and MCEE 2018
 Prepared by the Data and Analytics Section; Division of Data, Research and Policy, UNICEF.
 Last updated 5 February 2019
 Downloaded from: <https://data.unicef.org/topic/child-survival/under-five-mortality/>

Streptococcus pneumoniae, commonly known as pneumococcal disease, is the leading cause of pneumonia – the world’s number one killer of children under five years of age.

According to UNICEF*, Pneumonia kills approximately 2,400 children every day, with the vast majority of these deaths occurring in developing countries.

The most effective way to prevent these deaths is to ensure that all children have access to safe, affordable vaccines.

To accelerate the development and production of a new generation of pneumococcal vaccines, more targeted at the needs of developing countries and more affordable, GAVI, the World Bank and donors launched the pneumococcal Advance Market Commitment (AMC) in 2009.

GAVI countries rolling out pneumococcal vaccines will potentially avert more than 600,000 future deaths in the 2016 to 2020**.

*UNICEF Data, June 2018: <https://data.unicef.org/topic/child-health/pneumonia/>


** Gavi prospectus: The 2016-2020 Gavi, the Vaccine Alliance Investment Opportunity, May 2014.

Country immunisation profile: Mozambique

Total population (2018)	30,338,918
Birth cohort (2018)	1,141,595
Surviving Infants (surviving to 1 year per year, 2018)	1,077,629
Infant mortality rate (deaths < 1 year per 1000 births, 2015)	57/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015)	79/1000
World Bank Index, IDA (2015)	3.48
Gross Nation Income (per capita US\$, 2015)	590
No. of districts/territories (2017)	161



Non-vaccine support	Vaccine support
12%	88%
\$29,953,731	\$211,482,560



3

Gavi Matching Fund report

**Use of Bill & Melinda Gates
Foundation Matching Fund funds
corresponding to the contributions
channelled through “la Caixa” in 2018**

Use of Bill & Melinda Gates Foundation Matching Fund funds corresponding to the contributions channelled through “la Caixa” in 2018



FINANCIAL STATEMENT ON FUNDS UTILIZATION GATES MATCHING FUNDS FOR LA CAIXA

Details of contributions matched, funds allocated to Gavi programmes, and funds allocated in advance of being matched by the Gates Matching Fund

Table 1: 2018 Contributions matched by the Gates Matching Fund as of 28 February 2019

Description or reference	Amount of contribution matched in US\$
Gates Matching Funds for 2018 Funding from La Caixa Foundation	1,143,794
Total 2018 contributions matched by the Gates Matching Fund as of 28 February 2019	1,143,794

Table 2: Funds allocated to Gavi programmes as of 28 February 2019

Programme description	Implementing country	Date of fund allocations	Amount of funds allocated in US\$
Pneumococcal Programmes (CTN 2018-475)	Mozambique	03 April 2018	322,893
Pneumococcal Programmes (CTN 2018-527)	Mozambique	28 June 2018	1,108,715
Pneumococcal Programmes (CTN 2018-593)	Mozambique	24 September 2018	1,109,071
Pneumococcal Programmes (CTN 2019-406)	Mozambique	22 November 2018	1,213,288
Pneumococcal Programmes (CTN 2019-443)	Mozambique	11 February 2019	806,350
Total funds allocated to Gavi programmes as of 28 February 2019			4,560,318

Table 3: Funds allocated in advance of being matched by the Gates Matching Fund as of 28 February 2019

Description	Amount in US\$
Total contributions matched by the Gates Matching Fund, per Table 1 above	1,143,794
Total funds allocated to Gavi programmes, per Table 2 above	(4,560,318)
Funds allocated in advance of being matched by the Gates Matching Fund as of 28 February 2019	(3,416,524)

Notes:

1. US\$ 1,109,335 of the Pneumococcal Programme for Mozambique in this CTN was sponsored by the Gates Matching Funds. Of this total, US\$ 786,442 was covered by the Gates Matching Funds for La Caixa's 2017 contributions, and was, therefore, reported as allocated in the previous Financial Statement on Funds Utilization as of 15 April 2018. The remaining US\$ 322,893 was covered by the Gates Matching Funds for La Caixa's 2018 contributions, and was, therefore, reported as allocated in this Financial Statement on Funds Utilization.

2. This figure represents the amount of contribution raised by La Caixa via its 2018 Business Alliance for Childhood Vaccination, Employees' Donations and/or Public Microdonations Campaigns, that has yet to be matched by the Gates Matching Funds. Gavi will be requesting for the match in Q2 2019, and we expect this to be accepted by the Gates Foundation.

Prepared By:

Christine Le Doeuff
Senior Finance Manager, Contribution and Partner Grants

Certified By:

Pauline Caywood
Interim Head of Financial Accounting and Reporting

Date:

30-Apr-19

Thank You!

